Published October 1, 2026
Pick up a generic prescription and the receipt might say $12, or $40, or $200. The pharmacy's invoice for those same pills might say $0.57. Both numbers are real. The distance between them is the most misunderstood gap in American health care, and there is a free government dataset that measures one side of it every single week.
It is called NADAC, the National Average Drug Acquisition Cost. The Centers for Medicare and Medicaid Services surveys retail pharmacies about the invoice prices they actually paid wholesalers, averages the responses, and publishes the file weekly. It covers roughly 93 to 97 percent of covered outpatient drugs. It is the closest thing the public has to a true wholesale price for prescription drugs.
The two-cent pill
Take amlodipine, one of the most prescribed blood pressure drugs in the country. Its NADAC has sat around $0.019 per pill. A 30-day supply costs the pharmacy about $0.57 to acquire. Now look at what moves around that number: the Average Wholesale Price, a published list price sometimes called "ain't what's actually charged," can sit at $2.38 per pill for the same drug. A health plan might pay its pharmacy benefit manager $0.48 per pill under an "AWP minus 80 percent" contract. The plan pays 48 cents for a pill the pharmacy bought for 2 cents.
Atorvastatin tells the same story at a different scale. The generic version of Lipitor costs pharmacies pennies per pill at NADAC, while the brand version can run hundreds of dollars a month at list price. This is not a scandal and not a bargain. It is just what a competitive generic market does: once several manufacturers make the same molecule, the acquisition price collapses toward the cost of production.
The $1,302 prescription and the $299 one
Brand drugs are where NADAC gets genuinely startling. Independent researchers tracking GLP-1 weight-loss drugs against NADAC found that a pharmacy pays about $1,302 a month at NADAC acquisition cost for certain branded GLP-1 products, while cash-pay programs sell the same therapy to patients for as low as $299 a month. The gap is not pharmacy margin. NADAC measures what the pharmacy pays the wholesaler; it says nothing about dispensing costs, manufacturer rebates, or what a manufacturer charges through a channel it owns directly. The two prices live in different channels: insurance routes patients into the pharmacy channel where the $1,302 sits, while the $299 is a cash price from a buyer with no coverage.
The same NADAC file revealed a packaging quirk worth knowing about: one manufacturer sells the same GLP-1 at the same dose in two containers, and the pharmacy's monthly acquisition cost differs by hundreds of dollars between them. Same drug, same dose, different box. Nobody would know without the weekly file.
Why this matters to you
Three practical uses. First, if you pay cash for generics, NADAC tells you the floor. A $40 cash price on a drug with a $1 NADAC means there is room to shop around, try a discount card, or ask about a different pharmacy. Second, if your copay exceeds the NADAC-implied cost, ask your pharmacist whether paying cash is cheaper than running it through insurance. It sometimes is. Third, when a drug's price spikes, NADAC shows whether pharmacies are paying more too, which tells you whether the problem is at the wholesaler level or somewhere downstream.
What NADAC does not tell you matters too. It excludes off-invoice discounts and rebates, so the true net cost to a pharmacy can be lower than the published number. It is a national average, so your local independent pharmacy may pay more or less than the figure. And it covers acquisition only, not the cost of keeping a pharmacist on staff to dispense your prescription safely.
My honest take
I think NADAC is the most underused transparency tool in health care. It is free, weekly, and official, and it answers the question everyone asks at the counter: "why does this cost so much?" The answer is usually not "because the pharmacy paid a lot for it." Sometimes the answer is rebates and middlemen. Sometimes it is just the list price system doing what it was designed to do. Either way, you cannot have an informed opinion about drug prices without knowing the acquisition number, and now you know where to find it.
Frequently asked questions
What is NADAC?
The National Average Drug Acquisition Cost: a weekly CMS survey of what retail pharmacies actually paid wholesalers for prescription drugs, published as a public file. It is a measure of pharmacy acquisition cost, not retail price.
How is NADAC different from the price I pay?
NADAC is what the pharmacy paid to stock the drug. Your price adds the pharmacy's dispensing cost, its margin, and whatever your insurer or PBM negotiated, minus any rebates that flow elsewhere in the chain.
Does NADAC include rebates pharmacies receive?
No. NADAC is based on invoice prices and does not account for off-invoice discounts, rebates, or other price concessions. Net acquisition costs can be lower than the published NADAC figure.
Look up what pharmacies pay for your drug.
The NADAC Drug Price Lookup searches the official CMS weekly file across 340 common drugs. Free, no account, no estimates.
Educational reference only: NADAC figures are national averages from the CMS weekly file. Your pharmacy may pay more or less. Nothing here is medical or financial advice.